See more : Gores Technology Partners, Inc. (GTPAW) Income Statement Analysis – Financial Results
Complete financial analysis of Arcutis Biotherapeutics, Inc. (ARQT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcutis Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jiangxi Qixin Group Co., Ltd. (002781.SZ) Income Statement Analysis – Financial Results
- NACL Industries Limited (NACLIND.NS) Income Statement Analysis – Financial Results
- Gawk Incorporated (GAWK) Income Statement Analysis – Financial Results
- Noxopharm Limited (NOX.AX) Income Statement Analysis – Financial Results
- Fusion Fuel Green PLC (HTOO) Income Statement Analysis – Financial Results
Arcutis Biotherapeutics, Inc. (ARQT)
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 59.61M | 3.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.99M | 754.00K | 763.00K | 455.00K | 195.00K | 0.00 | 0.00 |
| Gross Profit | 54.62M | 2.93M | -763.00K | -455.00K | -195.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 91.63% | 79.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M | 17.94M | 3.41M |
| General & Administrative | 0.00 | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 185.15M | 122.12M | 60.97M | 21.34M | 6.61M | 1.80M | 695.00K |
| Other Expenses | 0.00 | 5.82M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Operating Expenses | 295.72M | 304.56M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Cost & Expenses | 300.71M | 305.31M | 206.53M | 136.65M | 43.13M | 19.74M | 4.11M |
| Interest Income | 0.00 | 9.83M | 173.00K | 967.00K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 29.71M | 15.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 1.25M | 763.00K | 455.00K | 195.00K | 19.74M | 4.11M |
| EBITDA | -227.43M | -294.55M | -205.59M | -135.22M | -41.80M | 480.00K | -872.00K |
| EBITDA Ratio | -381.56% | -8,025.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M | -19.74M | -4.11M |
| Operating Income Ratio | -404.49% | -8,183.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -17.93M | -9.83M | 173.00K | 967.00K | 1.14M | 480.00K | -872.00K |
| Income Before Tax | -259.03M | -311.46M | -206.36M | -135.68M | -42.00M | -19.26M | -4.98M |
| Income Before Tax Ratio | -434.57% | -8,449.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.11M | 9.83M | -454.00K | -84.30K | 23.14K | -480.00K | -4.11M |
| Net Income | -262.14M | -321.29M | -205.90M | -135.68M | -42.00M | -19.26M | -4.98M |
| Net Income Ratio | -439.79% | -8,716.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| EPS Diluted | -3.78 | -5.84 | -4.17 | -3.80 | -1.10 | -0.53 | -0.14 |
| Weighted Avg Shares Out | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
| Weighted Avg Shares Out (Dil) | 69.31M | 55.03M | 49.41M | 35.67M | 38.09M | 36.24M | 36.24M |
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
Arcutis Announces Pricing of $150 Million Public Offering
Arcutis Announces Proposed Public Offering
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports